Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 
Christine M.  Lovly

Christine M. Lovly, M.D., Ph.D.

Assistant Professor of Medicine (Hematology/Oncology)
Assistant Professor of Cancer Biology
Medical Oncologist

  • Appointments
    615-936-8422
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Henry-Joyce Cancer Clinic
    (615) 936-8422 or 1 (877) 936-8422

    Office
    615-936-3457
  • Faxes
    Henry-Joyce Cancer Clinic Fax
    (615) 343-8668

    Clinic Fax
    615-343-7602
  • Addresses
    Henry-Joyce Cancer Clinic
    1301 Medical Center Drive, Suite 1710
    Nashville, Tennessee 37232-7415
    Website

    Office
    Vanderbilt-Ingram Cancer Center
    2220 Pierce Ave South
    777 Preston Research Building
    Nashville, TN 37232
Profile

Dr. Lovly is a physician-scientist with a special interest in thoracic malignancies. She received a B.A. in chemistry from Johns Hopkins University followed by M.D. and Ph.D. degrees as part of the Medical Scientist Training Program at Washington University in St.
Read more...

Dr. Lovly is a physician-scientist with a special interest in thoracic malignancies. She received a B.A. in chemistry from Johns Hopkins University followed by M.D. and Ph.D. degrees as part of the Medical Scientist Training Program at Washington University in St. Louis, MO. She then completed internal medicine residency and medical oncology subspecialty training at Vanderbilt University. During her final year of fellowship, she was the Jim and Carol O'Hare Chief Fellow. She started on faculty at Vanderbilt in the Department of Medicine, Division of Hematology-Oncology in July 2012. Dr. Lovly's clinical practice focuses primarily on the care of patients with lung cancer. Her laboratory research is directed at understanding and developing improved therapeutic strategies for specific clinically relevant molecular subsets of lung cancer. Dr. Lovly has received independent grant funding from Uniting Against Lung Cancer and the Conquer Cancer Foundation of the American Society of Clinical Oncology. She is the author of several peer-reviewed scientific manuscripts, and she is an active member in the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC), and the American Association for Cancer Research (AACR). She is also deputy editor for the website www.mycancergenome.org, a Vanderbilt initiated, freely available website which aims to provide health care practitioners, patient, and advocates with up-to-date information regarding genetically informed cancer medicine.

Education
  • 1993-1997 B.A. in ChemistryGeneral Honors and Departmental HonorsJohns Hopkins University, Baltimore, MD
  • 1997-2006 M.D. and Ph.D. degreesWashington University School of Medicine, St. Louis, MO
  • 2006-2008 Resident in Internal MedicineVanderbilt University School of Medicine, Nashville, TN
  • 2008-2012 Clinical Fellow in Hematology and Oncology Vanderbilt University School of Medicine, Nashville, TN
  • 2011- 2012 Jim and Carol O'Hare Chief Fellow in Hematology-OncologyVanderbilt University School of Medicine, Nashville, TN
Publications
  • Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, Red Brewer M, York SJ, Kris MG, Pietenpol JA, Ladanyi M, Miller VA, Ali SM, Meiler J, Lovly CM. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Cancer Discov [print-electronic]. 2015 Nov; 5(11): 1155-63. PMID: 26286086, PMCID: PMC4631701, PII: 2159-8290.CD-15-0654, DOI: 10.1158/2159-8290.CD-15-0654, ISSN: 2159-8290.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26286086.
  • Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. J. Clin. Oncol [print-electronic]. 2015 Oct 10/5/2015; PMID: 26438117, PII: JCO.2015.62.0138, DOI: 10.1200/JCO.2015.62.0138, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26438117.
  • Iams WT, Lovly CM. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade. Clin. Cancer Res. 2015 Oct 10/1/2015; 21(19): 4270-7. PMID: 26429980, PMCID: PMC4593065, PII: 21/19/4270, DOI: 10.1158/1078-0432.CCR-14-2518, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26429980.
  • Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat. Med [print-electronic]. 2015 Sep; 21(9): 1038-47. PMID: 26301689, PII: nm.3930, DOI: 10.1038/nm.3930, ISSN: 1546-170X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26301689.
  • Iams WT, Lovly CM. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer. Cancer J. 2015 Sep; 21(5): 378-82. PMID: 26389762, PII: 00130404-201509000-00005, DOI: 10.1097/PPO.0000000000000142, ISSN: 1540-336X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26389762.
  • Ichihara E, Lovly CM. Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer. Cancer Discov. 2015 Jul; 5(7): 694-6. PMID: 26152920, PMCID: PMC4499857, PII: 5/7/694, DOI: 10.1158/2159-8290.CD-15-0616, ISSN: 2159-8290.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26152920.
  • Meador CB, Lovly CM. Liquid biopsies reveal the dynamic nature of resistance mechanisms in solid tumors. Nat. Med. 2015 Jul; 21(7): 663-5. PMID: 26151324, PII: nm.3899, DOI: 10.1038/nm.3899, ISSN: 1546-170X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26151324.
  • Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin. Cancer Res. 2015 May 5/15/2015; 21(10): 2227-35. PMID: 25979929, PMCID: PMC4435823, PII: 21/10/2227, DOI: 10.1158/1078-0432.CCR-14-2791, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25979929.
  • Hornick JL, Sholl LM, Dal Cin P, Childress MA, Lovly CM. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. Mod. Pathol [print-electronic]. 2015 May; 28(5): 732-9. PMID: 25612511, PII: modpathol2014165, DOI: 10.1038/modpathol.2014.165, ISSN: 1530-0285.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25612511.
  • Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. Cancer Immunol Res [print-electronic]. 2015 May; 3(5): 464-9. PMID: 25649350, PMCID: PMC4420706, PII: 2326-6066.CIR-14-0217, DOI: 10.1158/2326-6066.CIR-14-0217, ISSN: 2326-6074.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25649350.
  • Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M. MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. Clin. Cancer Res [print-electronic]. 2015 Apr 4/15/2015; 21(8): 1935-43. PMID: 25351745, PMCID: PMC4401580, PII: 1078-0432.CCR-14-2124, DOI: 10.1158/1078-0432.CCR-14-2124, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25351745.
  • Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res. 2015 Mar; 3(3): 288-95. PMID: 25736262, PMCID: PMC4351797, PII: 3/3/288, DOI: 10.1158/2326-6066.CIR-14-0207, ISSN: 2326-6074.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25736262.
  • Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, Riely GJ. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Thorac Oncol. 2015 Mar; 10(3): 431-7. PMID: 25415430, PMCID: PMC4479120, DOI: 10.1097/JTO.0000000000000432, ISSN: 1556-1380.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25415430.
  • Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, Lovly CM, Cross DA, Pao W. Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer. Mol. Cancer Ther [print-electronic]. 2015 Feb; 14(2): 542-52. PMID: 25477325, PMCID: PMC4338015, PII: 1535-7163.MCT-14-0723, DOI: 10.1158/1535-7163.MCT-14-0723, ISSN: 1538-8514.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25477325.
  • Lovly CM. Combating acquired resistance to tyrosine kinase inhibitors in lung cancer. Am Soc Clin Oncol Educ Book. 2015; e165-73. PMID: 25993168, PII: 0011500e165, DOI: 10.14694/EdBook_AM.2015.35.e165, ISSN: 1548-8756.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25993168.
  • Yu HA, Riely GJ, Lovly CM. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin. Cancer Res [print-electronic]. 2014 Dec 12/1/2014; 20(23): 5898-907. PMID: 25303979, PMCID: PMC4253858, PII: 1078-0432.CCR-13-2437, DOI: 10.1158/1078-0432.CCR-13-2437, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25303979.
  • Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. J Natl Compr Canc Netw. 2014 Nov; 12(11): 1629-49. PMID: 25361808, PII: 12/11/1629, ISSN: 1540-1413.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25361808.
  • Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretic L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat. Med [print-electronic]. 2014 Sep; 20(9): 1027-34. PMID: 25173427, PMCID: PMC4159407, PII: nm.3667, DOI: 10.1038/nm.3667, ISSN: 1546-170X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25173427.
  • Lovly CM, Gupta A, Lipson D, Otto G, Brennan T, Chung CT, Borinstein SC, Ross JS, Stephens PJ, Miller VA, Coffin CM. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov [print-electronic]. 2014 Aug; 4(8): 889-95. PMID: 24875859, PMCID: PMC4125481, PII: 2159-8290.CD-14-0377, DOI: 10.1158/2159-8290.CD-14-0377, ISSN: 2159-8290.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24875859.
  • Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24797823.
  • Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin. Cancer Res. 2014 May 5/1/2014; 20(9): 2249-56. PMID: 24789032, PMCID: PMC4029617, PII: 20/9/2249, DOI: 10.1158/1078-0432.CCR-13-1610, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24789032.
  • Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin. Cancer Res [print-electronic]. 2014 May 5/1/2014; 20(9): 2264-75. PMID: 24599935, PMCID: PMC4008689, PII: 1078-0432.CCR-13-1591, DOI: 10.1158/1078-0432.CCR-13-1591, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24599935.
  • Lammers PE, Lovly CM, Horn L. A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. J Natl Compr Canc Netw. 2014 Jan; 12(1): 6-11; quiz 11. PMID: 24453288, PMCID: PMC4151469, PII: 12/1/6, ISSN: 1540-1413.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24453288.
  • Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretic L, Seidel D, Zander T, Leenders F, George J, Müller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmüller J, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soltermann A, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M, Ansén S, Stoelben E, Wright GM, Russell P, Wainer Z, Solomon B, Field JK, Hyde R, Davies MP, Heukamp LC, Petersen I, Perner S, Lovly CM, Cappuzzo F, Travis WD, Wolf J, Vingron M, Brambilla E, Haas SA, Buettner R, Thomas RK. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun. 2014; 5: 3518. PMID: 24670920, PMCID: PMC4132974, PII: ncomms4518, DOI: 10.1038/ncomms4518, ISSN: 2041-1723.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24670920.
  • Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA, Pao W. Characteristics of lung cancers harboring NRAS mutations. Clin. Cancer Res [print-electronic]. 2013 May 5/1/2013; 19(9): 2584-91. PMID: 23515407, PMCID: PMC3643999, PII: 1078-0432.CCR-12-3173, DOI: 10.1158/1078-0432.CCR-12-3173, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23515407.
  • Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov [print-electronic]. 2013 Apr; 3(4): 430-43. PMID: 23533265, PMCID: PMC4086149, PII: 2159-8290.CD-12-0440, DOI: 10.1158/2159-8290.CD-12-0440, ISSN: 2159-8290.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23533265.
  • Baikadi M, Lovly C, Horn L, Reckamp KL, Noonan K, Laskin J, Morris GJ. A 75-year-old man with progressive bronchioalveolar carcinoma. Semin. Oncol. 2013 Feb; 40(1): e1-8. PMID: 23391120, PII: S0093-7754(12)00203-5, DOI: 10.1053/j.seminoncol.2012.11.004, ISSN: 1532-8708.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23391120.
  • Horn L, Lovly C. Update on HER1-3 in advanced non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5): S369-71. PMID: 23160321, PII: 01243894-201212005-00003, DOI: 10.1097/JTO.0b013e31826defaa, ISSN: 1556-1380.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23160321.
  • Lovly CM, Horn L. Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC. Curr Treat Options Oncol. 2012 Dec; 13(4): 516-26. PMID: 22833206, DOI: 10.1007/s11864-012-0204-6, ISSN: 1534-6277.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22833206.
  • Levy MA, Lovly CM, Pao W. Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Res [print-electronic]. 2012 Nov; 22(11): 2101-8. PMID: 23019146, PMCID: PMC3483539, PII: gr.131128.111, DOI: 10.1101/gr.131128.111, ISSN: 1549-5469.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23019146.
  • Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, Meder L, Lovly CM, Heukamp LC, Pao W, Küppers R, Thomas RK. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin. Cancer Res [print-electronic]. 2012 Sep 9/1/2012; 18(17): 4682-90. PMID: 22912387, PII: 1078-0432.CCR-11-3260, DOI: 10.1158/1078-0432.CCR-11-3260, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22912387.
  • Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol [print-electronic]. 2012 Mar 3/10/2012; 30(8): 863-70. PMID: 22215748, PMCID: PMC3295572, PII: JCO.2011.35.6345, DOI: 10.1200/JCO.2011.35.6345, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22215748.
  • Lovly CM, Pao W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med. 2012 Feb 2/8/2012; 4(120): 120ps2. PMID: 22323827, PII: 4/120/120ps2, DOI: 10.1126/scitranslmed.3003728, ISSN: 1946-6242.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22323827.
  • Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS ONE [print-electronic]. 2012; 7(4): e35309. PMID: 22536370, PMCID: PMC3335021, PII: PONE-D-12-03589, DOI: 10.1371/journal.pone.0035309, ISSN: 1932-6203.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22536370.
  • Heuckmann JM, Hölzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Grütter C, Rauh D, Pao W, Thomas RK. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin. Cancer Res [print-electronic]. 2011 Dec 12/1/2011; 17(23): 7394-401. PMID: 21948233, PMCID: PMC3382103, PII: 1078-0432.CCR-11-1648, DOI: 10.1158/1078-0432.CCR-11-1648, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21948233.
  • Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res [print-electronic]. 2011 Jul 7/15/2011; 71(14): 4920-31. PMID: 21613408, PMCID: PMC3138877, PII: 0008-5472.CAN-10-3879, DOI: 10.1158/0008-5472.CAN-10-3879, ISSN: 1538-7445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21613408.
  • Lovly CM, Carbone DP. Lung cancer in 2010: One size does not fit all. Nat Rev Clin Oncol. 2011 Feb; 8(2): 68-70. PMID: 21278771, PII: nrclinonc.2010.224, DOI: 10.1038/nrclinonc.2010.224, ISSN: 1759-4782.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21278771.
  • Lovly CM, Yan L, Ryan CE, Takada S, Piwnica-Worms H. Regulation of Chk2 ubiquitination and signaling through autophosphorylation of serine 379. Mol. Cell. Biol [print-electronic]. 2008 Oct; 28(19): 5874-85. PMID: 18644861, PMCID: PMC2547006, PII: MCB.00821-08, DOI: 10.1128/MCB.00821-08, ISSN: 1098-5549.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18644861.
  • King JB, Gross J, Lovly CM, Piwnica-Worms H, Townsend RR. Identification of protein phosphorylation sites within Ser/Thr-rich cluster domains using site-directed mutagenesis and hybrid linear quadrupole ion trap Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun. Mass Spectrom. 2007; 21(21): 3443-51. PMID: 17918214, DOI: 10.1002/rcm.3223, ISSN: 0951-4198.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17918214.
  • Bernal-Mizrachi L, Lovly CM, Ratner L. The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc. Natl. Acad. Sci. U.S.A [print-electronic]. 2006 Jun 6/13/2006; 103(24): 9220-5. PMID: 16751281, PMCID: PMC1482593, PII: 0507809103, DOI: 10.1073/pnas.0507809103, ISSN: 0027-8424.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16751281.
  • King JB, Gross J, Lovly CM, Rohrs H, Piwnica-Worms H, Townsend RR. Accurate mass-driven analysis for the characterization of protein phosphorylation. Study of the human Chk2 protein kinase. Anal. Chem. 2006 Apr 4/1/2006; 78(7): 2171-81. PMID: 16579595, DOI: 10.1021/ac051520l, ISSN: 0003-2700.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16579595.
  • Schwarz JK, Lovly CM, Piwnica-Worms H. Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. Mol. Cancer Res. 2003 Jun; 1(8): 598-609. PMID: 12805407, ISSN: 1541-7786.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12805407.
  • Graves PR, Lovly CM, Uy GL, Piwnica-Worms H. Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene. 2001 Apr 4/5/2001; 20(15): 1839-51. PMID: 11313932, DOI: 10.1038/sj.onc.1204259, ISSN: 0950-9232.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11313932.
  • Morgan SE, Lovly C, Pandita TK, Shiloh Y, Kastan MB. Fragments of ATM which have dominant-negative or complementing activity. Mol. Cell. Biol. 1997 Apr; 17(4): 2020-9. PMID: 9121450, PMCID: PMC232049, ISSN: 0270-7306.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9121450.